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Summary
Background: The mitotic kinases, Cdk1, Aurora A/B,
and Polo-like kinase 1 (Plk1) have been characterized
extensively to further understanding of mitotic mecha-
nisms and as potential targets for cancer therapy.
Cdk1 and Aurora kinase studies have been facilitated
by small-molecule inhibitors, but few if any potent Plk1
inhibitors have been identified.
Results: We describe the cellular effects of a novel
compound, BI 2536, a potent and selective inhibitor
of Plk1. The fact that BI 2536 blocks Plk1 activity fully
and instantaneously enabled us to study controversial
and unknown functions of Plk1. Cells treated with BI
2536 are delayed in prophase but eventually import
Cdk1-cyclin B into the nucleus, enter prometaphase,
and degrade cyclin A, although BI 2536 prevents deg-
radation of the APC/C inhibitor Emi1. BI 2536-treated
cells lack prophase microtubule asters and thus poly-
merize mitotic microtubules only after nuclear-enve-
lope breakdown and form monopolar spindles that do
not stably attach to kinetochores. Mad2 accumulates
at kinetochores, and cells arrest with an activated spin-
dle-assembly checkpoint. BI 2536 prevents Plk1’s en-
richment at kinetochores and centrosomes, and when
added to metaphase cells, it induces detachment of
microtubules from kinetochores and leads to spindle
collapse.
Conclusions: Our results suggest that Plk1’s accu-
mulation at centrosomes and kinetochores depends
on its own activity and that this activity is required
for maintaining centrosome and kinetochore function.
Our data also show that Plk1 is not required for
prophase entry, but delays transition to prometa-
phase, and that Emi1 destruction in prometaphase
*Correspondence: peters@imp.univie.ac.atis not essential for APC/C-mediated cyclin A degra-
dation.
Introduction
In eukaryotes from yeast to men, orthologs of Polo-like
kinase 1 (Plk1) control multiple essential steps of mito-
sis and meiosis (reviewed in [1]). In vertebrate cells,
Plk1 has been implicated in the activation of Cdk1-
cyclin B at mitotic entry [2–5], centrosome maturation
[6], release of cohesin from chromosome arms [7–9],
activation of the anaphase promoting complex/cyclo-
some (APC/C) by direct phosphorylation [10, 11] and
by inactivation of the APC/C inhibitor Emi1 [12, 13], for-
mation of bipolar spindles [14, 15], and accumulation of
spindle assembly checkpoint (SAC) proteins at kineto-
chores [16–18]. Plk1 is believed to perform this multi-
tude of functions by specific recruitment to substrates
via its Polo-box domain (PBD). The PBD interacts with
Plk1 substrates by binding to phosphosites, which are
generated by ‘‘priming kinases’’ such as Cdk1 or by
Plk1 itself [18–21]. It has been proposed that the inter-
actions with multiple substrates result in Plk1’s locali-
zation to diverse structures in the mitotic cell, where
Plk1 is found at centrosomes, at unattached kineto-
chores, and in late mitosis at the cytokinetic furrow
and midbody [1, 22].
In a number of cases, the study of protein kinases has
been greatly facilitated by the identification of specific
small-molecule inhibitors. For example, several com-
pounds have been described that inhibit Aurora kinases
[23–26] and Cdks (reviewed in [27]). In contrast, com-
pounds that inhibit Plk1 have only been developed
recently. However, in our analyses the first reported
compound, called ON01910 [28], did not inactivate
Plk1 efficiently in vitro or in vivo (see [29]; this issue of
Current Biology). After the submission of this manu-
script, two other compounds were reported to inhibit
Plk1, but the specificity and potency of these inhibitors
in human cells remain to be further investigated [30, 31].
We have developed a compound, BI 2536, that in-
hibits Plk1 with high potency (IC50 = 0.83 nM). This com-
pound shows more than 1,000-fold selectivity against a
large panel of protein kinases, but it affects the activities
of other Polo-kinase family members, such as Plk2/Snk
(IC50 = 3.5 nM) and Plk3/Fnk (IC50 = 9 nM; for technical
reasons we have not yet been able to determine the ef-
fect of BI 2536 on Plk4/SAK). However, with the excep-
tion of Plk1, all other Polo family members are thought
to function during G1 and S phases of the cell cycle (re-
viewed in [22]), and therefore BI 2536 is expected to
specifically target Plk1 in mitotic cells. To directly test
this, we first compared cellular effects of BI 2536 to
published Plk1 RNAi data. Because BI 2536 mirrored
phenotypes of Plk1 RNAi, we used this compound to
analyze Plk1 functions that could not or not reliably be
addressed by RNAi experiments.
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305Figure 1. BI 2536 Specifically Blocks Plk1-Dependent Mitotic Events in a Dose-Dependent Manner
(A) Asynchronous populations of HeLa cells were treated for 2 hr with or without BI 2536 and stained for g-tubulin and the centriole marker centrin
(cen3). g-tubulin is shown in red, and centrin is shown in green. The scale bar represents 10 mm.
(B) Quantification of centrosomal g-tubulin levels at different concentrations of BI 2536 for mitotic cells processed as in (A). Total centrosomal
intensity relative to the intensity in a same-size cytoplasmic region is shown (n > 20 each, average values 6 SD).
(C) HeLa cells stably expressing the Myc-tagged cohesin subunit Scc1 were treated for 3 hr with 100 ng/ml Nocodazole or a combination of
Nocodazole and 100 nM BI 2536; mitotic cells were shaken off and immunostained with the antibodies indicated. Scale bars represent 10 mm.
(D) Quantification of Scc1-9myc expressing cells of (C).Results
BI 2536 Specifically Inhibits Plk1 Functions
in Mitosis
The high potency and selectivity of BI 2536 in vitro
and the mitotic arrest caused by BI 2536 in cultured
cell lines and mouse tumor xenografts implied that BI
2536 also inhibits Plk1 in vivo [29]. To further test the
selectivity of BI 2536, we investigated, in HeLa cells,
several mitotic processes that are known to be depen-
dent on Plk1.
First, we quantified the Plk1-dependent accumula-
tion of g-tubulin and the pApc6 phosphoepitope at mi-
totic centrosomes in cells treated with increasing con-
centrations of BI 2536 [6, 11, 32]. We found an almost
identical dose-dependent reduction of both centroso-
mal g-tubulin and pApc6 staining with full efficacy at
100 nM (Figures 1A and 1B; see also Figures S1A andS1B in the Supplemental Data available with this article
online).
Second, we followed the release of cohesin from chro-
mosome arms, a process that also depends on Plk1
[7–9]. Cohesin remained associated with chromosome
arms, and arm cohesion was maintained even after pro-
longed mitotic arrest in BI 2536-treated cells, whereas in
Nocodazole-treated control cells, cohesin was removed
from chromosomes except for centromeric regions (Fig-
ures 1C and 1D; Figures S1C and S1D).
Taken together, these observations indicate that BI
2536 is a potent inhibitor of Plk1 in human cultured cells.
Because in dose-response experiments, 100 nM BI 2536
induced a well-defined set of fully penetrant pheno-
types, which faithfully recapitulated the effects of Plk1
RNAi, our data further suggest that Plk1 is maximally
and specifically inhibited by treatment with 100 nM BI
2536 [29].
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of Time in Prophase and Enter Prometaphase
at a Reduced Rate
In Xenopus oocyte extracts, depletion of the Plk1 ortho-
log Plx1 prevents activation of Cdk1 and mitotic entry
[33], whereas depletion of Plk1 by RNAi in HeLa cells de-
lays but does not prevent mitotic entry [12, 15]. Because
the latter result could be caused by incomplete Plk1 de-
pletion, we analyzed mitotic entry in HeLa cells that were
treated with BI 2536.
We synchronized HeLa cells by double thymidine
arrest and released them in the absence or presence
of BI 2536 or Monastrol, a compound that arrests cells
in prometaphase by inhibiting the kinesin Eg5 [34]. At
different time points, cells were fixed, DNA was stained
with DAPI, and mitotic stages were classified by chro-
mosome morphology.
In both control and Monastrol-treated populations,
cells began to enter mitosis 4 hr after thymidine release,
and Monastrol-treated cells accumulated in prometa-
phase, whereas untreated cells exited mitosis (Fig-
ure 2A). BI 2536-treated cells accumulated in mitosis at
a very similar rate to Monastrol-treated cells. Interest-
ingly however, up to 30% of BI 2536-treated cells were
in prophase, compared to only 5%–10% in the control
or Monastrol-treated populations (Figure 2A). BI 2536
did not cause this delay in prophase indirectly by inter-
fering with progression through S or G2 phase because
we observed a similar increase in the occurrence of pro-
phases when we added the compound 3 or 6 hr after
release from thymidine (Figure S2A). We also found an
almost identical increase of prophase populations by
using histone 3 phosphorylated on Ser10 (H3S10ph), a
marker that labels prophase cells in a specific dotted
pattern (Figures S2B and S2C). Taken together, these
data suggest that in human cells Plk1 inhibition does
not interfere with entry into prophase but that Plk1 is
required for timely entry into prometaphase.
We confirmed these observations at the single-cell
level by filming HeLa cells that stably express a GFP-
tagged version of the core histone H2B. These experi-
ments revealed that nuclear-envelope breakdown
(NEBD) only occurred several hours after chromosome
condensation in BI 2536-treated cells, whereas control
cells spent only 15–30 min between the initiation of
condensation and NEBD (Figure 2C and Movie S1). As
a consequence, the rate of entry into prometaphase
was decreased by half in BI 2536-treated populations
as compared to untreated controls (Figure 2B).
Entry into prometaphase is driven by activation of
Cdk1-cyclin B. Plk1 has been proposed to activate Cdk1
through phosphorylation of the phosphatase Cdc25C
[33], degradation of the kinase Wee1 [2], and by phos-
phorylation of cyclin B. Cyclin B phosphorylation by
Plk1 was suggested to be required for nuclear translo-
cation of Cdk1-cyclin B [3] and for activation of Cdk1-
cyclin B at the centrosomes [5].
It is unclear how Plk1’s functions—many of which
have only been studied in vitro—are coordinated in cells.
Therefore, we prepared total extracts of HeLa cells at
different times after thymidine release into media con-
taining Nocodazole with or without BI 2536 and analyzed
these samples by immunoblotting. As expected, Cdk1
activation (detected by increased electrophoreticmobility of Cdk1) was delayed in BI 2536-treated cells
by approximately 4 hr, (Figure 2D). BI 2536 also pre-
vented timely Wee1 degradation and Cdc25C phosphor-
ylation (which retards the electrophoretic mobility of
Cdc25C) (Figure 2D). To analyze the effects of Plk1 activ-
ity on cyclin B, we also filmed cells expressing cyclin
B-YFP. In Monastrol-treated control cells, cyclin B first
accumulated at centrosomes and entered the nucleus
approximately 12 min before NEBD (as previously re-
ported for untreated cells [35], Figure 3A). In contrast,
cyclin B did not accumulate at centrosomes in BI 2536-
treated cells, but cyclin B eventually entered the nucleus
with normal kinetics (Figure 3A). Taken together, these
data indicate that Plk1 is required for phosphorylation
of Cdc25C, degradation of Wee1, and centrosomal re-
cruitment of cyclin B but not for nuclear import of
Cdk1-cyclin B. Our results further imply that these func-
tions of Plk1 are not absolutely essential for entry into
prometaphase, although they are required for timely
progression to this stage of mitosis.
BI 2536-Treated Cells Arrest in Prometaphase and
Initiate Cyclin A Destruction without Degrading Emi1
Degradation of the APC/C inhibitor Emi1 in mitotic cell
extracts has been shown to depend on Plk1 activity
[12, 13], and it has been proposed that Emi1 destruction
is required for degradation of cyclin A in prometaphase.
However, controversial results have been obtained
when Plk1 was depleted from HeLa cells by RNAi be-
cause a delay in cyclin A degradation was reported in
one [12] but not in two other studies [11, 14]. We there-
fore analyzed the kinetics of both Emi1 and cyclin A deg-
radation in BI 2536-treated cells by transfecting them
with either cyclin A-YFP [36] or Emi1-YFP. We analyzed
Monastrol-treated cells, which showed Emi1 and cyclin
A degradation kinetics similar to untreated cells, as
controls (Figure S3D; [36]).
In control cells, Emi1 degradation was initiated 10–20
min before NEBD and was complete 20 min after NEBD
(Figure 3B), whereas the destruction of cyclin A was
initiated at NEBD (Figure 3C). In BI 2536-treated cells,
Emi1 degradation was delayed by at least 1 hr, but cyclin
A levels nevertheless decayed with kinetics similar to
those seen in Monastrol-treated cells (Figures 3B and
3C). Immunoblot experiments showed that BI 2536 treat-
ment also resulted in increased levels of endogenous
Emi1 in mitotic cells (Figure S3C).
Our data are therefore consistent with the notion that
Plk1 activity is required for degradation of Emi1, but our
results indicate that Emi1 degradation is not essential
for cyclin A destruction. Thus, in vivo the properties of
Emi1 may be similar to those of its Drosophila ortholog
Rca1. This protein has been shown to inhibit APC/C dur-
ing interphase when APC/C is activated by Cdh1, but
Rca1 does not antagonize the activity of APC/CCdc20 in
mitosis [37]. A recent, detailed study of nondegradable
Emi1 mutants led to similar conclusions (B.D.F. and J.
Pines, unpublished data).
BI 2536 Treatment Leads to Spindle-Assembly-
Checkpoint-Induced Prometaphase Arrest
Depletion of Plk1 by RNAi has previously been shown to
cause a prometaphase arrest in which cyclin A is de-
graded but cyclin B is not [14, 15]. Similarly, we observed
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307Figure 2. BI 2536-Treated Cells Enter Prophase Normally, but Their Transition into Prometaphase Is Delayed
(A) HeLa cells were synchronized by double thymidine arrest, fixed, and stained with DAPI at the indicated times after the second release. Drugs
were added at t = 0, and 100 cells were staged at each time point.
(B) Quantification of the experiment shown in (C). A cumulative plot of cells that progressed through NEBD is shown in percentage of the total cell
number (n = 113 and 115 for the control and BI 2536 treatment, respectively).
(C) Selected frames from a time-lapse series of HeLa cells expressing H2B-GFP after thymidine release in the presence or absence of BI 2536.
Time is shown in minutes, and t = 0 is set to NEBD. The scale bar represents 10 mm. For the full movie, see Movie S1.
(D) Immunoblots of total cell lysates of synchronized HeLa cells. Either Nocodazole or Nocodazole and BI 2536 were added at the time of
thymidine release and extracts were prepared at the indicated times after release. Abbreviations are as follows: P, phosphorylated form; NP,
non-phosphorylated form.that BI 2536-treated cells arrested in prometaphase and
that neither cyclin B-YFP nor endogenous cyclin B
were degraded in these cells, although both cyclin A-
YFP and endogenous cyclin A were destroyed (Figures
3A and 3C; Figures S3A and S3B). These observations
are consistent with the possibility that BI 2536-treatedcells arrest in prometaphase because of activation of
the SAC.
To further test this possibility, we treated BI 2536 ar-
rested cells with Hesperadin, a compound that can over-
ride the SAC by inhibiting the kinase Aurora B [24]. When
we filmed untreated HeLa cells that express H2B-GFP,
Current Biology
308Figure 3. Inhibition of Plk1 by BI 2536 Prevents Degradation of Emi1 but Does Not Affect Kinetics of Cyclin A and Cyclin B Degradation
(A) HeLa cells were transfected with cyclin B-YFP and synchronized by a single thymidine treatment. Imaging was started 4 hr after the thymidine
release, and 100 nM BI 2536 or 100 mM Monastrol was added to the medium at the same time. Hoechst 33342 was added to stain DNA for
identifying prophase cells with condensed chromatin. Stacks of six images were acquired every minute; selected single frames and time points
are shown. Time is shown in minutes relative to NEBD. The chart shows quantification of average fluorescence intensities measured in the
nuclear region. Intensities were normalized between the maximal intensity and background outside the cells. Averages and standard deviations
are plotted (n = 5).
(B) HeLa cells were transfected with Emi1-YFP and synchronized as in (A). Average projections for selected time points are shown (nR 5, each).
Quantification, as in (A), is shown. Note that the apparent increase in Emi1 intensity after NEBD in BI 2536-treated cells is caused by rounding up
of mitotic cells.
(C) Cells were transfected with cyclin A-YFP and imaged and quantified as in (A), nR 5 each.
Scale bars for all panels represent 10 mm.all cells entered and rapidly exited mitosis (Figures 4A
and 4B). Similarly, most Hesperadin-treated cells exited
mitosis, but these cells formed multilobed nuclei be-
cause of failure of chromosome segregation (Figures
4A and 4B). In contrast, all BI 2536-treated cells arrested
in mitosis, and most entered apoptosis directly from the
mitotic arrest (Figures 4A and 4B). However, when cellswere treated with a combination of Hesperadin and BI
2536, cells exited mitosis and formed multilobed nuclei
similar to cells treated with Hesperadin alone (Figures
4A and 4B). Consistently, cyclin B levels were high in to-
tal lysates of cells arrested in mitosis by Nocodazole or
BI 2536 (Figure 4D, lanes 2–4), but low levels were found
in cells treated with Hesperadin and Hesperadin in
BI 2536 Reveals Novel Insights into Plk1 Function
309Figure 4. BI 2536 Treatment Leads to Spindle-Assembly-Checkpoint-Induced Prometaphase Arrest
(A) HeLa cells stably expressing H2B-GFP were synchronized by thymidine arrest and imaged after release in the presence of 100 nM Hesper-
adin, 100 nM BI 2536, a combination of the two drugs, or an equal amount of DMSO as the control. Selected cells representing the typical be-
havior of the population are shown at the start of recording, at the time of mitotic entry, at exit from mitosis or apoptosis, and at the end of the
experiment. The scale bar represents 10 mm.
(B) Quantification of (A). For each cell filmed, the red bar represents the time spent in mitosis (defined by the time from NEBD to chromosome
decondensation), and the gray bars indicate apoptosis. The numbers indicate the average and standard deviation of the time spent in mitosis
(hh:mm).
(C) Asynchronous populations of HeLa cells were treated for 2 hr with 100 nM BI 2536, fixed, and stained for the indicated checkpoint proteins,
and CREST was used as a centromeric marker. Maximum-intensity projections of three deconvolved 150 nm image sections are shown. Check-
point protein is shown in green; CREST is shown in red. Scale bars represent 10 mm.
(D) Immunoblots of total cell lysates of cells 13 hr after the second thymidine release. 100 nM BI 2536, 50 ng/ml Nocodazole, 100 nM Hesperadin,
or combinations of those were added at release from the second thymidine arrest.combination with BI 2536 (Figure 4D, lanes 5 and 6).
Thus, our data imply that BI 2536 treatment leads to ac-
tivation of the SAC and that Plk1 activity is not essential
for APC/C activation and mitotic exit.
Although Plk1 depletion was known to activate the
SAC, the behavior of SAC proteins in Plk1 depleted cells
has remained controversial. Depletion of Plk1 did not
prevent the enrichment of Mad2 and BubR1 at kineto-
chores in some studies [14, 15], whereas others reported
that depletion of Plk1 or Plx1 did prevent these interac-
tions [16–18]. We therefore analyzed Mad2, BubR1,
and also Bub1 by immunofluorescence microscopy inBI 2536-treated cells. In control prometaphase cells,
we could clearly distinguish kinetochores that were
either brightly or only dimly stained (Figure 4C and Fig-
ure S4B). Previous work has shown that the dim and
bright signals represent kinetochores that are fully or
not fully attached to microtubules, respectively [38, 39].
In cells arrested by BI 2536, more than 90% of kineto-
chores were brightly and homogeneously stained for all
three SAC proteins (Figure 4C and Figure S4A). Quantifi-
cation of these signals showed that the intensities on
these kinetochores were similar to brightly labeled kinet-
ochores of control cells, with the possible exception of
Current Biology
310Figure 5. BI 2536 Prevents Plk1 Recruitment to Mitotic Centrosomes and Unattached Kinetochores
(A) Asynchronous populations of HeLa cells were treated with 100 nM BI 2536 for 2 hr, fixed, and processed for immunofluorescence. Maximum-
intensity projections of stacks of deconvolved 150 nm sections are shown. The scale bar represents 10 mm.
(B) Centrosomal Plk1 staining was compared to the cytoplasmic signal in 10 prometaphase cells treated with or without BI 2536. Ratios and stan-
dard deviations are shown.
(C) Examples showing outer kinetochore staining of Plk1. For quantification of intensities, 100 kinetochores from at least five different cells were
measured each in control prometaphase, control metaphase, and BI 2536 prometaphase arrest. Ratios to cytoplasmic staining and standard
deviations are shown.BubR1, whose kinetochore levels were slightly reduced
by BI 2536 (Figure S4B). In immunoblot experiments,
we also noticed that BubR1’s mitotic mobility shift,
which is caused by phosphorylation [40], was abolished
when cells entered mitosis in the presence of BI 2536
(Figure 4D, compare lanes 3 and 4). Our data therefore
indicate that Plk1 activity is not required for the re-
cruitment of Mad2, Bub1, and BubR1 to unattached
kinetochores, although Plk1 may be needed for BubR1
phosphorylation.
BI 2536 Prevents Plk1 Recruitment
to Centrosomes and Kinetochores
The PBD of Plk1 is required for the recruitment of Plk1 to
mitotic centrosomes and for enrichment of Plk1 at unat-
tached kinetochores [41]. The PBD has been proposed
to mediate these interactions by binding to phospho-
sites that are generated by Cdk1 [20, 42], but in some
cases, it has also been reported that Plk1 can create
its own phosphosite for PBD binding [18, 21, 43].
We therefore tested whether Plk1 activity is required
for the correct subcellular localization of Plk1 in early mi-
tosis. In control cells, Plk1 antibodies clearly stainedcentrosomes and unattached kinetochores (Figure 5A).
In contrast, after BI 2536 treatment, centrosomes were
labeled weakly and only dim kinetochore signals were
observed in prometaphase arrested cells (Figures 5A–
5C). Although BI 2536-treated cells arrest with kineto-
chores that are not occupied by a full complement of
microtubules (see below), the intensity of Plk1 staining
at these kinetochores was reduced more than 10-fold,
to a level similar to the intensity of Plk1 staining at
kinetochores in control metaphase cells (Figures 5A
and 5C).
Our data therefore suggest that Plk1 activity is
essential for the proper recruitment of Plk1 to mitotic
centrosomes and unattached kinetochores. We cannot
exclude the possibility that BI 2536 prevents Plk1 recruit-
ment indirectly; however, recent findings by others have
shown that Plk1 itself can create phosphoepitopes
that are recognized by the PBD at kinetochores [18]. It
is therefore conceivable that once recruited to these lo-
cations, Plk1 activity may initiate a positive feedback
loop that could result in rapid and high levels of local
accumulation of Plk1 at the sites where it performs its
functions.
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(A) TC21 cells expressing a-tubulin-GFP and CENP-A-GFP were synchronized by a single thymidine arrest, treated with or without 100 nM BI
2536 4 hr after release, and imaged. Hoechst 33342 was added for identifying cells in prophase. Six z planes were acquired 1 mm apart every
minute. Maximum-intensity projections of deconvolved images are shown for selected time points. Time is shown in minutes; t = 0 is set to
NEBD. The scale bar represents 10 mm. For the full movie, see Movie S2.
(B) As in (A), except that cells were arrested for 2 hr with 10 mM MG 132 and BI 2536 was added at t = 0. Images were taken every 5 min. For the full
movie, see Movie S3.
(C) Cells treated with or without 100 nM BI 2536 for 2 hr, fixed, and stained for NuMa (green) and tubulin (red). The scale bar represents 10 mm.
(D) In an experiment similar to (B), cells were stained for Mad2 so that the status of the spindle assembly checkpoint could be assessed. The scale
bar represents 10 mm.BI 2536 Inhibits Formation and Maintenance
of Centrosomal Microtubule Asters
Plk1 is known to be required for the recruitment of g-tu-
bulin to mitotic centrosomes and for the formation of
functional bipolar spindles [6, 14, 15]. However, it has
not been analyzed in kinetic terms how microtubules
behave in the absence of Plk1 activity and whether this
activity is continuously required once bipolar spindles
have been formed.
To address these questions, we generated a HeLa cell
line (TC21) that stably coexpresses GFP-tagged ver-
sions of a-tubulin and of the centromere-specific his-
tone CENP-A. Live cell imaging of these cells revealed
that centrosomes started to nucleate short and dynamic
mitotic microtubule asters approximately 10 min before
NEBD (Movie S2). Thereafter, microtubules rapidly cap-
tured kinetochores and aligned them on a bipolar spin-
dle in less than 10 min (Figure 6A and Movie S2). In con-
trast, prophase microtubule asters were undetectable
in BI 2536-treated cells (Figure 6A and Movie S2; for
immunofluorescence data, see Figure S5). In these cells,
mitotic microtubules appeared only after NEBD, and
these microtubules were instantaneously organized
into a monopolar spindle (Figure 6A and Movie S2).Because this spindle configuration is very similar to
the phenotype of the first described polo mutants in
Drosophila [44], we refer to these structures as ‘‘Polo’’
spindles. The microtubule minus-end cross-linker
NuMa [45] was enriched at the center of these ‘‘Polo’’
spindles, suggesting that NuMa and other microtubule
associated proteins might organize microtubules in the
absence of centrosomal nucleation (Figure 6C). The
monopolar phenotype was not caused by unspecific
inhibition of Eg5, in light of the fact that the ATPase ac-
tivity of Eg5 was unaffected by BI 2536 in vitro (data not
shown).
Taken together, our data imply that Plk1 activity is es-
sential for centrosomal microtubule nucleation and that
these centrosomal microtubule asters might have a
prominent role in prophase, but our data also imply
that centrosome independent mechanisms are able to
mediate microtubule polymerization after NEBD as has
been observed in noncentrosomal cells.
To address whether Plk1 is also required for maintain-
ing centrosome function, we treated TC21 cells with
MG132, a proteasome inhibitor that arrests cells with
bipolar spindles in which all kinetochores are attached
to microtubules (Figures 6B and 6D). Live cell imaging
Current Biology
312Figure 7. Plk1 Inhibition by BI 2536 Prevents Establishment and Maintenance of Stable Microtubule-Kinetochore Attachments
(A–D) Asynchronous populations of HeLa cells stably expressing CENPA-GFP were treated for 2 hr with 100 nM BI 2536, 100 mM Monastrol, or left
untreated and were fixed and processed for immunofluorescence. Maximum-intensity projections of deconvolved stacks (‘‘projection’’) or max-
imum-intensity projections of three 150 nm sections (‘‘section’’) are shown. Insets show magnified views of kinetochore attachments. Centro-
meres (CENPA-GFP) are shown in green, a-tubulin is shown in red, and g-tubulin is shown in blue. Scale bars represent 5 mm.
(E) TC21 cells were treated with BI 2536 or Monastrol. Deconvolved single optical sections are shown. The scale bar represents 5 mm.
(F) HeLa cells were treated with BI 2536 or Monastrol for 2 hr, put on ice for 15 min, fixed, and stained for a-tubulin (red) and CREST (green).
Maximum-intensity projections of three deconvolved 150 nm sections are shown. The scale bar represents 5 mm.
(G) Thin section electron micrographs of kinetochores in cells treated with BI 2536 or Monastrol. The scale bar represents 200 nm.revealed that spindles remained in this state for at least
2 hr (Figure 6B). However, when BI 2536 was added,
spindles lost astral microtubules and focused poles
within 10–30 min (Figure 6B and Movie S3). Thereafter,
spindle poles often broadened (Figure 6B, 30 min) and
several kinetochore pairs lost biorientation (Figure 6B,
60 min). Finally, spindles shortened and suddenly col-
lapsed into a ‘‘Polo’’ spindle (Figure 6B, 120 min; Movie S3).
We also performed immunofluorescence microscopy
on fixed cells at different times after the addition of BI
2536. As in live cells, we found that spindles first lostfocused poles (Figures S6A and S6B, 30 min) and short-
ening and collapse followed (Figures S6A and S6B, 60
and 120 min). Concomitantly, centrosomes detached
from the spindle, moved toward the spindle equator,
and gradually lost g-tubulin staining (Figure S6A).
Taken together, our results indicate that Plk1 activity is
required for maintaining the association of g-tubulin with
centrosomes and is necessary for continuous nucleation
of microtubules from centrosomes. Similar findings have
recently been obtained in experiments involving purified
Drosophila centrosomes [30].
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of Kinetochore Fibers
It has been suggested that Plk1 [15] or Plk1 recruitment
to kinetochores by NudC is required for generation of
stable microtubule-kinetochore attachments [43]. How-
ever, it has not been analyzed in detail how microtubules
interact with kinetochores in cells lacking Plk1 activity.
To understand which of the spindle abnormalities in
BI 2536-treated cells might be indirectly caused by the
monopolar nature of these spindles, we analyzed Mon-
astrol-treated cells as controls because these cells
also form monopolar spindles. Monastrol-treated cells
possessed very distinguishable kinetochore fibers (K-
fibers), which held kinetochore pairs within a narrow
range of 3.456 0.16 mm from the spindle center. In con-
trast, kinetochore pairs in BI 2536-treated cells were
scattered and on average located further away from
the spindle center (4.57 6 0.54 mm). Moreover, Monas-
trol spindles were composed mostly of K-fibers, much
like untreated metaphase cells (Figures 7B and 7D). In
contrast, ‘‘Polo’’ spindles contained many thinner and
longer microtubules, most of which did not end at kinet-
ochores (Figure 7A), reminiscent of prometaphase cells
where chromosomes are being captured and K-fibers
are not yet established (Figure 7C). We could visualize
similar structures in live cells (Figure 7E), indicating
that microtubule structures were preserved by our fixa-
tion protocol.
To confirm that BI 2536-treated cells cannot establish
stable K-fibers, we used cold treatment to depolymerize
microtubules that are not part of K-fibers [46]. In BI 2536-
treated cells, we could not visualize any microtubule
structures after cold treatment, whereas K-fibers per-
sisted in Monastrol-treated cells (Figure 7F).
To directly visualize microtubule-kinetochore attach-
ments, we examined thin sections of BI 2536-treated
cells by transmission electron microscopy. Also in this
case, we compared ‘‘Polo’’ spindles with Monastrol-
treated cells. Two major differences were apparent:
In Monastrol-treated cells, ‘‘end-on’’ attachments of mi-
crotubule bundles were visible at many kinetochores
(Figure 7G) and the majority of kinetochore plates were
arranged on a tangent relative to the spindle center (Fig-
ure S7). In contrast, kinetochores in BI 2536-treated cells
were only connected to a few, if any, microtubules, and
these attachments were often lateral (Figure 7G). Fur-
thermore, in BI 2536-treated cells, the kinetochores
were oriented in various directions and often faced the
opposite side of the chromosomes relative to the spin-
dle center (Figure S7).
Taken together, our data suggest that Plk1 activity is
essential for the establishment of stable microtubule-
kinetochore attachments. It is possible that kineto-
chores can be captured by microtubules in the absence
of Plk1 activity, but these attachments may not be stable
and proper K-fibers may therefore not be formed. Deple-
tion of BubR1 by RNAi also causes defects in micro-
tubule-kinetochore attachments [23, 47]. Because BI
2536-treated cells lack the mitotic hyperphosphorylated
form of BubR1 (see above, Figure 4D), Plk1 might con-
tribute to K-fiber formation by phosphorylation of BubR1
at kinetochores.
To address whether Plk1 activity is also required for
the maintenance of K-fibers, we analyzed TC21 cellsthat had been arrested in MG132 and subsequently
treated with BI 2536. As described above, bipolar spin-
dles collapsed 1–2 hr after the addition of BI 2536. At
the same time, thick K-fibers disappeared and were re-
placed by thinner microtubule bundles (Figure 6B).
Moreover, we also observed that Mad2 was rerecruited
to kinetochores in cells fixed in similar conditions, indi-
cating that many of the microtubule-kinetochore attach-
ments had been dissolved after treatment with BI 2536
(Figure 6D). Our data therefore suggest that Plk1 activity
is required for not only the establishment but also the
maintenance of K-fibers.
Conclusions
Previous experiments have clearly established that Plk1
and its orthologs have a variety of essential roles in
mitosis. However, description of Plk1 inactivation phe-
notypes has been limited by the possibility that late mi-
totic functions could have been obscured by earlier
defects. Furthermore, in many experimental systems, it
has been difficult to assess whether Plk1 had been inac-
tivated completely. We have therefore used the small-
molecule inhibitor BI 2536 to reinvestigate functions
previously ascribed to Plk1 and to gain novel insights
to mitotic roles of Plk1. Our data imply that Plk1 has spe-
cific functions in Emi1 degradation, activation of Cdk1-
cyclin B, cohesin release, centrosome function, and
regulation of microtubule-kinetochore attachments. A
comparison of our results with previous data from
RNAi and biochemical experiments indicate strongly
that BI 2536 is a potent and specific inhibitor of Plk1 in
live human cells. BI 2536 will therefore be likely to serve
as a powerful tool in mitosis research.
Supplemental Data
Supplemental Data include Experimental Procedures, seven fig-
ures, and three movies and can be found with this article online at
http://www.current-biology.com/cgi/content/full/17/4/304/DC1/.
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